Brokerages Set Qiagen N.V. (NYSE:QGEN) Target Price at $42.43

Shares of Qiagen N.V. (NYSE:QGEN) have earned an average rating of “Hold” from the fourteen analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $43.9250.

A number of equities research analysts have recently commented on QGEN shares. Robert W. Baird set a $43.00 target price on shares of Qiagen and gave the company an “outperform” rating in a research report on Wednesday, April 29th. Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price objective on Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th.

Institutional Investors Weigh In On Qiagen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Danske Bank A S acquired a new position in Qiagen in the third quarter valued at $36,000. Manchester Capital Management LLC acquired a new position in Qiagen in the 4th quarter valued at about $42,000. Global Retirement Partners LLC raised its stake in Qiagen by 279.9% during the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares during the last quarter. Hilltop National Bank acquired a new stake in Qiagen during the 2nd quarter worth approximately $50,000. Finally, Advisory Services Network LLC acquired a new stake in Qiagen during the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of NYSE QGEN opened at $42.65 on Friday. Qiagen has a one year low of $32.53 and a one year high of $57.81. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The firm has a fifty day moving average of $39.72 and a 200 day moving average of $41.48. The firm has a market cap of $8.79 billion, a PE ratio of 21.86, a PEG ratio of 4.37 and a beta of 0.63.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The firm had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. Qiagen’s quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, research analysts predict that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.